SRX Global Inc. (SRXH)

SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results

SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger

SRX Global Acquires Shares in Jersey Mike's $1 Billion Initial Public Offering

SRX Global Regains Full Compliance with NYSE American Listing Standards

SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026